Vanda Pharmaceuticals/$VNDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
- Ticker
- $VNDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 533
- Headquarters
- Washington, United States
- Website
- www.vandapharma.com
VNDA Metrics
BasicAdvanced
$305M
-
-$4.63
0.64
-
Price and volume
Market cap
$305M
Beta
0.64
52-week high
$9.94
52-week low
$4.27
Average daily volume
797K
Financial strength
Current ratio
1.612
Quick ratio
1.401
Long term debt to equity
0.083
Total debt to equity
0.083
Profitability
EBITDA (TTM)
-177.041
Gross margin (TTM)
93.74%
Net profit margin (TTM)
-127.41%
Operating margin (TTM)
-86.07%
Effective tax rate (TTM)
-55.11%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-22.38%
Return on equity (TTM)
-77.81%
Valuation
Price to revenue (TTM)
1.389
Price to book
1.38
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-1.959
Free cash flow yield (TTM)
-51.05%
Free cash flow per share (TTM)
-2.573
Growth
Revenue change (TTM)
6.02%
Earnings per share change (TTM)
304.80%
3-year revenue growth (CAGR)
-3.27%
10-year revenue growth (CAGR)
5.24%
3-year earnings per share growth (CAGR)
162.05%
10-year earnings per share growth (CAGR)
17.02%
What the Analysts think about VNDA
Analyst ratings (Buy, Hold, Sell) for Vanda Pharmaceuticals stock.
Analyst projections of the future price of Vanda Pharmaceuticals stock.
Bulls say / Bears say
Fanapt is showing genuine commercial momentum: Q2 net product sales rose 23% year on year to $36.0m, while total prescriptions rose 31%. FDA approval of BYSANTI for bipolar I disorder and schizophrenia, with a second-half 2026 launch, could extend Vanda’s psychiatry franchise as Fanapt matures. (PR Newswire)
NEREUS has a potentially larger growth path beyond motion sickness. In a Phase II GLP-1 study, vomiting occurred in 29.3% of tradipitant-treated participants versus 58.6% on placebo, and the confirmatory Phase III Thetis study is due to report in the fourth quarter of 2026. (PR Newswire)
Near-term regulatory catalysts could broaden the portfolio: Quimilza’s BLA for generalised pustular psoriasis is under FDA review with a 12 December 2026 PDUFA date, while Vanda is pursuing a formal FDA hearing for HETLIOZ in jet-lag disorder. These outcomes are not assured, but they offer upside beyond the current products. (PR Newswire)
HETLIOZ is in a steep decline: Q2 sales fell 66% year on year to $5.6m, even allowing for $7m of revenue shifted into Q3, as generic competition cut volume. A federal appeals court largely upheld the FDA and Teva’s position on the generic, leaving the erosion risk in place. (PR Newswire, Bloomberg Law)
Vanda is consuming cash rapidly while funding launches and trials. Cash fell to $170m by 30 June from about $263.8m at year-end, Q2 net loss reached $62.5m, and management expects 2026 cash burn to exceed 2025; the end-2027 runway therefore depends on planned cost reductions and revenue growth. (Quartr, The Motley Fool)
Fanapt’s growth faces a looming exclusivity problem: management says it expects the product to lose exclusivity towards the end of 2027, while BYSANTI is bioequivalent and may mainly switch existing Fanapt patients rather than add equivalent new demand. That could make the new launch defensive and pressure the franchise’s economics. (StockAnalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
VNDA Financial Performance
Revenues and expenses
VNDA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VNDA News
AllArticlesVideos
Funds containing VNDA
AllUSDEURGBP
Fund name | Fund size | $VNDA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.03% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.03% |
iShares Ageing Population€AGED | €822M | 0.03% |
iShares Healthcare Innovation£DRDR | £1B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.